We found in a big cohort of ALS patients that Aβ1-42 could be used to improve diagnosis, and our results suggest the putative role of phospho-Tau and total Tau protein in the CSF as markers for disease progression. The gene discussed is MAPT; the disease is amyotrophic lateral sclerosis.